In TP53 wild-type AML cells, the expression of downstream targets of the TP53 apoptotic signaling pathway, such as BAX, was significantly elevated at both the mRNA (MV4-11: control vs 0.5 μM cytarabine,P < 0.05; and MOLM-13: control vs 0.5 μM cytarabine,P < 0.05) and protein levels, whereas BCL2 expression was notably reduced (MV4-11: control vs 0.5 μM cytarabine,P < 0.05; and MOLM-13: control vs 0.5 μM cytarabine,P < 0.01) (Figure 1D,E). This evidence concerns the gene BAX and acute myeloid leukemia.